Chatterjee, Anuja
van de Wetering, Gijs
Goeree, Ron
Owen, Carolyn
Desbois, Anne Marie
Barakat, Stephane
Manzoor, Beenish S. http://orcid.org/0000-0002-0329-3465
Sail, Kavita
Funding for this research was provided by:
AbbVie
Article History
Accepted: 26 September 2022
First Online: 5 November 2022
Declarations
:
: AbbVie Inc. provided financial support for the study. Venetoclax is being developed in a collaboration between AbbVie Inc. and Genentech Inc. No honoraria or payments were made for authorship.
: Anuja Chatterjee: consultancy (AbbVie); Gijs van de Wetering: consultancy (AbbVie); Ron Goeree: consultancy (AbbVie); CO: honoraria (Abbvie, Astrazeneca, Janssen, Roche, Merck, Incyte); Anne Marie Desbois: employment and ownership interests (AbbVie); Stephane Barakat: employment and ownership interests (AbbVie); Beenish S. Manzoor: employment and ownership interests (AbbVie); Kavita Sail: employment and ownership interests (AbbVie).
: Not applicable.
: Not applicable.
: Not applicable.
: Input data for the generation of the results are available in this article and its Electronic Supplementary Material. Additional datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The MS Excel model cannot be shared because of confidentiality reasons.
: Not applicable.
: All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. AbbVie and Pharmerit, an OPEN Health Company participated in the design, study conduct, analysis and interpretation of data, as well as the writing, review, and approval of the manuscript.